Friday, December 22, 2023
Ono Pharmaceutical Co., Ltd. (based in Osaka, Japan, with Gyo Sagara serving as President and CEO) recently announced a collaborative agreement with EVQLV, INC (headquartered in Miami, Florida, USA, led by CEO Andrew Satz). The collaboration is focused on the development of innovative antibody drugs through the generation of novel antibodies against multiple targets selected by Ono.
Within the terms of the agreement, EVQLV will utilize its proprietary Artificial Intelligence (AI)-powered Antibody Design Engine to create therapeutic antibody designs for various targets specified by Ono. Ono will use these designs to produce potential antibodies, advancing the development and commercialization of antibody drug candidates. Throughout the research period, Ono will provide research funding and success-based research milestone payments to EVQLV. Additionally, Ono will retain option rights for the exclusive global development and commercialization of the resulting antibody drug candidates.
Dr. Toichi Takino, Senior Executive Officer and Executive Director of Discovery and Research at Ono, expressed enthusiasm about the collaboration, highlighting the potential of EVQLV's AI technology to expedite the creation of novel antibody candidates against multiple targets. The goal is to address unmet medical needs across a range of diseases and accelerate the discovery of innovative drugs for patients.
Andrew Satz, CEO and co-founder of EVQLV, acknowledged Ono's successful track record in identifying unique targets that have led to life-changing medicines. He emphasized EVQLV's mission to make AI easily accessible to researchers, aiming to enhance the success rates in drug discovery. Satz expressed honor in working with Ono's scientific and drug development experts, anticipating breakthrough options for patients in need through the collaboration.
Source: prnewswire.com
